Akebia Therapeutics (AKBA) Gross Margin (2018 - 2026)
Akebia Therapeutics (AKBA) reported Gross Margin of 78.78% for Q2 2026, down 5.34 percentage points from 84.12% a year earlier but up 1.74 percentage points from the prior quarter.
Powered by 
Analysis
Akebia Therapeutics (AKBA) Gross Margin (2018 - 2026) Analysis & Trends
Over the twelve months ended Jun 30, 2026, Akebia Therapeutics' Gross Margin came in at 79.63%, up 5.18 percentage points year-over-year; for FY2025, it was 83.29%, up 22.73 percentage points from FY2024.
- Gross Margin has a five-year change of +83.91 percentage points (FY2020 to FY2025).
- By year, Gross Margin came in at 60.56% in FY2024 (-1.34 pp), 61.90% in FY2023 (-8.84 pp), 70.74% in FY2022 (+41.93 pp) and 28.81% in FY2021 (+29.43 pp).
- Five-year quarterly Gross Margin spans a low of 17.42% in Q4 2021 and a high of 106.15% in Q4 2022.
- Year over year, Gross Margin gained in five of the last eight quarters, with an average year-over-year change of +8.60 percentage points.
- The high point for year-over-year Gross Margin in five years was Q4 2022 (a gain of 88.72 percentage points); the low point was Q3 2022 (a drop of 45.88 percentage points).
- Per Business Quant data, the three quarters before Q2 2026 came in at 77.05% (Q1 2026), 78.25% (Q4 2025) and 84.03% (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 83.88% |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 68.12% |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | 75.38% |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 72.95% |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 88.03% |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 73.10% |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | 81.07% |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 75.71% |
| 10 | Akebia Therapeutics | 149.86 Mn | -512.48 Mn | 30.54 Mn | 82.76% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 82.76% |
| Jun 30, 2026 | 78.78% |
| Mar 31, 2026 | 77.05% |
| Dec 31, 2025 | 78.25% |
| Sep 30, 2025 | 84.03% |
| Jun 30, 2025 | 84.12% |
| Mar 31, 2025 | 86.70% |
| Dec 31, 2024 | 56.20% |
| Sep 30, 2024 | 62.16% |
| Jun 30, 2024 | 60.94% |
| Mar 31, 2024 | 64.41% |
| Dec 31, 2023 | 66.79% |
| Sep 30, 2023 | 57.17% |
| Jun 30, 2023 | 69.34% |
| Mar 31, 2023 | 49.53% |
| Dec 31, 2022 | 106.15% |
| Sep 30, 2022 | 21.42% |
| Jun 30, 2022 | 85.28% |
| Mar 31, 2022 | 62.55% |
| Dec 31, 2021 | 17.42% |
API Access
Akebia Therapeutics Gross Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=gross-margin&ticker=AKBA&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "gross-margin", "ticker": "AKBA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=gross-margin&ticker=AKBA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();